<DOC>
	<DOCNO>NCT00933244</DOCNO>
	<brief_summary>The purpose study answer follow question : Does vitamin D increase calcium absorption , bone mass muscle mass function woman past menopause mildly low vitamin D level ? Do benefit require prescription-strength vitamin D , counter vitamin D dose enough ?</brief_summary>
	<brief_title>Treatment Vitamin D Insufficiency</brief_title>
	<detailed_description>Osteoporosis major health problem postmenopausal woman . At age 50 , half woman suffer osteoporotic fracture remain lifetime , cause increase disability mortality . Vitamin D deficiency , define serum 25 ( OH ) D &lt; 15 ng/mL , contribute osteoporosis via decreased calcium absorption ( Ca·Ab ) , secondary hyperparathyroidism ( HPT ) , increase bone resorption decrease bone mineral density ( BMD ) . Thus , expert agree patient vitamin D deficiency receive vitamin D therapy . Vitamin D insufficiency ( VDI ) milder form hypovitaminosis D define 25 ( OH ) D level 15 30 ng/mL regardless parathyroid hormone ( PTH ) status . Experts disagree whether treat VDI , clinical benefit therapy uncertain . Some expert insist optimal 25 ( OH ) D level ≥30 ng/mL . By contrast , Food Nutrition Board NIH Evidence Report No . 158 state insufficient evidence exists declare optimal serum 25 ( OH ) D bone health , despite review ~170 study . Consequently , Food Nutrition Board determine recommend daily allowance vitamin D. Confusion optimal 25 ( OH ) D level result , part , previous trial fail recruit subject base initial 25 ( OH ) D level and/or fail target achieve 25 ( OH ) D level ≥30 ng/mL . Moreover , secondary HPT , propose mechanism VDI cause bone loss , occur 10 % 33 % people VDI . As , people VDI normal PTH might experience clinical benefit vitamin D therapy . VDI widespread , affect 26 % 39 % postmenopausal American woman without osteoporosis . Therefore , determine ideal 25 ( OH ) D level optimal calcium homeostasis bone health utmost clinical public health importance . Our overall goal , congruent Healthy People 2010 objective 2-9 , evaluate effect vitamin D therapy risk osteoporosis postmenopausal woman VDI , reflect change Ca·Ab , BMD muscle fitness . Our second goal evaluate whether high-dose vitamin D regimen , choose achieve maintain 25 ( OH ) D level ≥30 ng/mL , superior effect study outcome compare low-dose vitamin D regimen permit continued VDI . We conduct randomize , placebo-controlled double-blind trial low-dose high-dose vitamin D postmenopausal woman vitamin D insufficiency order investigate follow aim : 1 . To evaluate effect vitamin D3 therapy Ca·Ab postmenopausal woman less equal 75 year old VDI . Sub-aims include investigation subject variable influence Ca·Ab 25 ( OH ) D level baseline one month , accuracy oral isotope plasma level Ca·Ab measurement ability questionnaire identify patient low vitamin D status . 2 . To evaluate effect vitamin D3 therapy 12-month change BMD bone turnover trial conduct Aim 1 . Sub-aims include identification subject variable significantly influence change BMD evaluation relationship change Ca·Ab change BMD . 3 . To evaluate effect vitamin D therapy muscle mass functional capacity trial conduct Aim 1 . We measure muscle mass whole body bone densitometry assess muscle function use Timed Up Go ( TUG ) Test modify Stanford Health Assessment Questionnaire ( HAQ ) score . Sub-aims include identification subject variable significantly influence muscle outcome .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Vitamin D insufficiency , define serum 25 ( OH ) D 16 25 ng/mL high performance liquid chromotography assay Women ≥ 5 year past date last menses bilateral oophorectomy , ≥ 60 year old prior hysterectomy without bilateral oophorectomy Total dietary supplemental calcium intake &lt; 600 mg daily ≤ 1,400 mg daily , base food frequency questionnaire Women &gt; 75 year old Hypercalcemia ( serum calcium correct albumin &gt; 10.4 mg/dL ) Nephrolithiasis medical record patient report Inflammatory bowel disease , malabsorption chronic diarrhea Stage 3 , 4 5 Chronic Kidney Disease base Modification Renal Diet ( MDRD ) formula Use boneactive medication within past 6 month include bisphosphonates , estrogen compound , calcitonin , teriparatide , oral corticosteroid anticonvulsant Allergy intolerance orange juice Allergy intolerance sunscreen Prior adult clinical fragility fracture hip , spine wrist Tscore 2.5 lumbar spine femur</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Cholecalciferol</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>Calcium Absorption</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Muscle Function</keyword>
</DOC>